Arcturus Therapeutics(NASDAQ) ARCT

Market Cap$164.57M

Since IPO (2017)-43%

5 Year-82%

1 Year-56%

1 Month-15%

$5.78

+0.52%

+0.03Today

Arcturus Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 5.79	2026-07-29

Arcturus Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.36%	USD 5.93	2026-07-22
1 month	-15.1%	USD 6.82	2026-06-29
3 month	-32.83%	USD 8.62	2026-04-30
Year to date	-5.55%	USD 6.13	2025-12-31
1 year	-55.67%	USD 13.06	2025-07-29
3 year	-83.14%	USD 34.34	2023-07-28
5 year	-81.51%	USD 31.31	2021-07-30
Since inception	-42.56%	USD 10.01	2017-11-17

Arcturus Therapeutics Financials at a Glance

Market Cap

$164.57M

Revenue (TTM)

$45.35M

Net Income (TTM)

-$78.67M

EPS (TTM)

-$2.82

P/E Ratio

-2.06

Dividend

$0.00

Beta (Volatility)

2.02 (High)

Dividend

$0.00

Beta (Volatility)

2.02 (High)

Price

$5.78

Volume

Open

$5.85

Price

$5.78

Volume

Open

$5.85

Previous Close

$5.79

Daily Range

$5.62 - $5.90

52-Week Range

$5.50 - $24.17

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

2.02 (High)

Price

$5.78

Volume

Open

$5.85

Previous Close

$5.79

Daily Range

$5.62 - $5.90

52-Week Range

$5.50 - $24.17

Estimated Earnings Date

Aug 10, 2026

ARCT News

vaccine COVID coronavirus pandemic health

Page 1

ARCT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arcturus Therapeutics

Arcturus creates medicines that use genetic instructions to help bodies fight diseases. Its products target rare liver and lung conditions and prevent viral infections. These treatments help patients who lack specific proteins or need vaccines.

The Medicine Cabinet

Self-amplifying mRNA Vaccines: Vaccine technology that makes copies of itself inside the body to provide protection at lower doses.
Lipid Delivery Systems: Tiny fatty particles that protect and carry medicine directly to target cells in the body.
Rare Disease Therapeutics: Genetic treatments for conditions like cystic fibrosis and liver disorders currently in clinical testing.

Charting the Path Forward

Collaborated with CSL Seqirus in 2022 to develop and sell vaccines for COVID-19 and influenza globally.
Secured a cost-reimbursement contract with BARDA to advance a low-dose flu vaccine platform.
Partnered with Meiji to launch an updated COVID-19 vaccine in Japan during August 2025.
Initiated arbitration against CSL Seqirus in May 2025 regarding a milestone payment for the European market.

What Makes Arcturus Different

The company developed the first self-amplifying RNA vaccine to receive commercial approval in major global markets. Its specialized delivery technology allows genetic medicine to reach specific tissues like the liver and lungs safely.

Checking the Ledger

Total revenue fell to $2.1 million in Q1 2026, a 93% decrease from $29.4 million in Q1 2025.
Net loss deepened to $27 million in Q1 2026 compared to a $14.1 million loss in Q1 2025.
Research and development expenses decreased 38% year-over-year to $21.5 million in the first quarter of 2026.
Cash and equivalents totaled $213.4 million as of March 31, 2026, down from $232.8 million at the start of the year.

The Final Word

Arcturus has shifted from a research firm to a commercial-stage vaccine and rare disease treatment developer. Its future relies on the success of its proprietary RNA platforms and international partnerships.

AI Generated • May 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

111

CEO

Joseph E. Payne

Website

www.arcturusrx.com

Headquarters

San Diego, CA 92121, US

ARCT Financials

Key Financial Metrics (TTM)

Gross Margin

91.18%

Operating Margin

-196.72%

Net Income Margin

-173.47%

Return on Equity

-36.55%

Return on Capital

-31.36%

Return on Assets

-32.06%

Earnings Yield

-48.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$164.57M

Shares Outstanding

28.42M

Volume

Avg. Volume

474.79K

Financials (TTM)

Gross Profit

$41.35M

Operating Income

-$89.22M

EBITDA

-$67.53M

Operating Cash Flow

-$58.57M

Capital Expenditure

-$318.66K

Free Cash Flow

-$58.89M

Cash & ST Invst.

$211.38M

Total Debt

$23.99M

Arcturus Therapeutics Performance Analysis

Arcturus Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 205,999,000	1566.8%
2023	2023-12-31	USD 157,748,000	-23.4%
2024	2024-12-31	USD 138,389,000	-12.3%
2025	2025-12-31	USD 67,221,000	-51.4%

Arcturus Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-16.6%
Q3	2025-09-30	-30.0%
Q4	2025-12-31	-82.0%
Q1	2026-03-31	-80.2%

Arcturus Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.35	N/A
2023	2023-12-31	USD -1.12	N/A
2024	2024-12-31	USD -3.00	168.5%
2025	2025-12-31	USD -2.40	-19.9%

Arcturus Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	34.6%
Q3	2025-09-30	-44.1%
Q4	2025-12-31	-114.3%
Q1	2026-03-31	9.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$610.00K

-97.9%

Gross Profit

-$48.00K

-100.2%

Gross Margin

-7.87%

N/A

Market Cap

$164.57M

N/A

Market Cap/Employee

$1.48M

N/A

Employees

111

N/A

Net Income

-$26.96M

-91.6%

EBITDA

-$26.31M

-98.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$211.38M

-2.6%

Total Debt

$23.99M

-43.8%

Accounts Receivable

$1.34M

-90.8%

Inventory

$0.00

N/A

Long Term Debt

$19.68M

-49.5%

Short Term Debt

$4.31M

+17.3%

Return on Assets

-32.06%

N/A

Return on Invested Capital

-42.27%

N/A

Free Cash Flow

-$19.44M

+44.9%

Operating Cash Flow

-$19.44M

+44.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.00-1.32%

IMRXImmuneering Corporation

IMRXImmuneering Corporation$4.06-4.36%

HUMAHumacyte, Inc.

HUMAHumacyte, Inc.$0.62-0.97%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$7.04-3.16%

TRDAEntrada Therapeutics, Inc.

TRDAEntrada Therapeutics, Inc.$6.55+12.35%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$4.74-7.60%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$5.05-2.13%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$19.63-0.20%

NOKNokia

NOKNokia$8.41-0.06%

SKHYSK Hynix

SKHYSK Hynix$126.79-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$6.74-0.06%

INTCIntel

INTCIntel$81.88-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$49.44+0.06%

Questions About ARCT

What is the current price of Arcturus Therapeutics?

Arcturus Therapeutics is trading at $5.79 per share.

What is the 52-week range for Arcturus Therapeutics?

Over the past 52 weeks, Arcturus Therapeutics has traded between $5.50 and $24.17.

How much debt does Arcturus Therapeutics have?

As of the most recent reporting period, Arcturus Therapeutics reported total debt of $23.99M.

How much cash does Arcturus Therapeutics have on hand?

Arcturus Therapeutics reported $211.38M in cash and cash equivalents in its most recent financial results.

What is Arcturus Therapeutics’s dividend yield?

Arcturus Therapeutics does not currently have a dividend yield.

Arcturus Therapeutics(NASDAQ) ARCT

Arcturus Therapeutics Financials at a Glance

ARCT News

Why Shares of Arcturus Therapeutics Dropped on Tuesday

Why Arcturus Therapeutics Stock Is Soaring Today

Why Arcturus Therapeutics Stock Is Skyrocketing Today

Could Arcturus Therapeutics Be the Next Moderna?

Why Arcturus Therapeutics Stock Was Up 16% Thursday

Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?

Why Arcturus Therapeutics Stock Is Soaring Today

Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?

ARCT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Arcturus Therapeutics

The Medicine Cabinet

Charting the Path Forward

What Makes Arcturus Different

Checking the Ledger

The Final Word

ARCT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Arcturus Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARCT

What is the current price of Arcturus Therapeutics?

What is the 52-week range for Arcturus Therapeutics?

How much debt does Arcturus Therapeutics have?

How much cash does Arcturus Therapeutics have on hand?

What is Arcturus Therapeutics’s dividend yield?

Premium Investing Services